Molecular structure of Ioversol, CAS Number: 87771-40-2
Ioversol (CAS 87771-40-2)
Alternate Names:
Optiray
Application:
Ioversol is a radiographic contrast agent
CAS Number:
87771-40-2
Purity:
98%
Molecular Weight:
807.11
Molecular Formula:
C18H24I3N3O9
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ioversol is a non-ionic, water-soluble radiopaque contrast agent employed in imaging studies to enhance the visibility of vascular structures and organs on radiographs. In research applications, it is used to investigate the vascular system, including studies on blood flow and vessel integrity. The compound′s high iodine content allows for effective absorption of X-rays, rendering the bloodstream and other fluid-filled spaces more visible under imaging techniques such as computed tomography (CT) and angiography. Researchers also utilize ioversol to understand the parameters affecting contrast enhancement and the kinetics of contrast agent distribution.
Ioversol (CAS 87771-40-2) References
- Hypersensitivity reaction to ioversol. | Alvarez-Fernández, JA., et al. 2000. Allergy. 55: 581-2. PMID: 10858993
- [Pharmacotoxicological profile of a non-ionic LOCM at high hydrophilicity: ioversol]. | Doucet, D. and Idée, JM. 1992. Ann Radiol (Paris). 35: 267-72. PMID: 1296489
- Fatal anaphylactoid reaction following ioversol administration. | Jansman, FG., et al. 2007. Pharm World Sci. 29: 584-6. PMID: 17557212
- Ioversol-induced acute generalized exanthematous pustulosis: a case report. | Hammerbeck, AA., et al. 2009. Arch Dermatol. 145: 683-7. PMID: 19528424
- Hemodynamic effects of ioversol in the dog and rat. | Ralston, WH., et al. 1989. Invest Radiol. 24 Suppl 1: S10-5. PMID: 2592167
- Dynamic Effects of Ioversol on the Permeability of the Blood-Brain Barrier and the Expression of ZO-1/Occludin in Rats. | Wang, H., et al. 2019. J Mol Neurosci. 68: 295-303. PMID: 30955191
- Ethiodized poppyseed oil versus ioversol for image quality and adverse events in hysterosalpingography: a prospective cohort study. | Tan, Y., et al. 2019. BMC Med Imaging. 19: 50. PMID: 31234782
- Contrast-enhanced micro-computed tomography of articular cartilage morphology with ioversol and iomeprol. | Ter Voert, CEM., et al. 2020. J Anat. 237: 1062-1071. PMID: 32683740
- Paricalcitol Attenuates Contrast-Induced Acute Kidney Injury by Regulating Mitophagy and Senescence. | Bae, E., et al. 2020. Oxid Med Cell Longev. 2020: 7627934. PMID: 33299530
- A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol in more than 57,000 patients: part 1-intravenous administration. | van der Molen, AJ., et al. 2022. Eur Radiol. 32: 5532-5545. PMID: 35312790
- Maculopapular rash due to delayed-type hypersensitivity from ioversol with positive patch tests. | Gómez Gratacos, AR., et al. 2022. Contact Dermatitis. 87: 379-381. PMID: 35687812
- Ioversol Induced Microglia Proinflammatory Activation and Oxidative Stress in Rats. | Li, T., et al. 2023. Neurotox Res. 41: 149-165. PMID: 36595162
- Clinical profile of ioversol. A metaanalysis of 57 randomized, double-blind clinical trials. | Floriani, I., et al. 1996. Invest Radiol. 31: 479-91. PMID: 8854194
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ioversol, 100 mg | sc-211655 | 100 mg | $317.00 | |||
Ioversol, 1 g | sc-211655A | 1 g | $515.00 | |||
Ioversol, 5 g | sc-211655B | 5 g | $1077.00 | |||
Ioversol, 10 g | sc-211655C | 10 g | $1685.00 | |||
Ioversol, 25 g | sc-211655D | 25 g | $2648.00 |